ArticleJournal of advanced research2026
Photo-crosslinkable hydrogel with programmable dual time-phase drug release for accelerated healing of infected diabetic wounds.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging biomaterials and immunotherapy: hydrogel strategies for next-generation CAR-T cell treatment.Stem cell research & therapy · 2026Review
- Electronic Skins for Advanced Wound Healing: Biomimetic Thermoregulation and Bioelectrically Active Systems.Polymers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic diabetic wounds remain a critical unmet challenge in clinical care, largely due to persistent bacterial infections and unresolved inflammation, leading to impaired healing. While photo-crosslinkable hydrogels offer localized therapeutic delivery, existing systems often face limitations in ease of modification and comprehensive multi-functional efficacy. Herein, we present a light-activated hydrogel dressing featuring programmable, dual time-phase drug release and simplified modification of crosslinking matrices to address these barriers in a synergistic manner. This intelligent system integrates a ciprofloxacin-caged photo-crosslinker (PCA-CIP), hyaluronic acid (HA), and metformin-loaded poly(lactic-co-glycolic acid) nanoparticles (MET@NPs). Upon brief photo-irradiation, the hydrogel rapidly crosslinks (<52 s), releasing ciprofloxacin immediately at the wound site for rapid anti-bacterial action. Concurrently, MET@NPs enable sustained delivery of metformin to modulate inflammation over an extended period. This spatiotemporally coordinated release, characterized by an initial burst of antibiotics followed by prolonged anti-inflammatory activity, fosters a favorable microenvironment for tissue regeneration. In both in vitro and full-thickness diabetic wound models, the hydrogel exhibits strong tissue adhesion, potent infection control, durable immunomodulation, and significantly enhanced healing. This work demonstrates the clinical promise of dual time-phase hydrogels as precision-engineered wound therapies for diabetes-related complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.